Prophylactic hyperthermic intraperitoneal chemotherapy in patients with locally advanced gastric cancer after curative surgery:Final results of a phase Ⅱ trial  

作　　者：Biao Fan Hao Su Lingqian Wang Xin Ji Yinan Zhang Ziyu Jia Ji Zhang Zhaode Bu Xiaojiang Wu 

机构地区：[1]Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing),Gastrointestinal Cancer Center,Peking University Cancer Hospital&Institute,Beijing 100142,China [2]State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers,Beijing Key Laboratory of Carcinogenesis and Translational Research,Gastrointestinal Cancer Center,Peking University Cancer Hospital&Institute,Beijing 100142,China

出　　处：《Chinese Journal of Cancer Research》2025年第1期66-72,共7页中国癌症研究(英文版)

基　　金：supported by the National Nature Science Foundation of China(No.81402308);Science Foundation of Peking University Cancer Hospital(No.2021-24);Natural Science Foundation of Beijing Municipal(No.7242020);Science Foundation of Peking University Cancer Hospital(No.BJCH2025GG04);the National Nature Science Foundation of China(No.82173151).

摘　　要：Objective:The trial was designed to evaluate the efficacy of prophylactic hyperthermic intraperitoneal chemotherapy(HIPEC)with cisplatin for patients with locally advanced gastric cancer(LAGC).Methods:Between March 2015 and November 2016,a phase Ⅱ clinical trial was performed.Fifty consecutive patients with LAGC were randomly assigned to two groups:the experimental group(radical gastrectomy+HIPEC with cisplatin+adjuvant chemotherapy)and the control group(radical gastrectomy+adjuvant chemotherapy).Survival rates were closely monitored.Results:The 5-year overall survival(OS)rate of all patients was 80.0%.The 5-year OS rate in the experimental group was lower than that in the control group,at 75.8%and 88.2%,respectively,with no statistical significance.In addition,5-year recurrence-free survival(RFS)rates of patients who underwent HIPEC or not were also 75.8%and 88.2%,respectively.In the multivariate analysis,only pT stage[risk ratio(RR)=7.079,P=0.018]was significantly associated with prognosis.The most common recurrence pattern was peritoneal recurrence in both groups.The experimental group had a lower incidence of peritoneal recurrence than the control group with no statistical significance.Conclusions:This trial clearly revealed that prophylactic HIPEC with cisplatin neither decrease the risk of peritoneal recurrence nor improve the prognosis of patients with LAGC.Thus,HIPEC with cisplatin is not recommended as a prophylactic treatment for peritoneal recurrence of LAGC after radical gastrectomy.

关 键 词：Gastric cancer intraperitoneal chemotherapy CISPLATIN PROGNOSIS 

分 类 号：R735.2[医药卫生—肿瘤]